Alen Xuring

$NWBO pin this tweet 👇

#NWBO $NWBO This is not just a collection of vaccine enthusiasts, this is a powerhouse conglomeration of biotech badasses! I was fortunate enough to meet Linda Powers in December (whom I spied in this picture!), but I was unfamiliar with her company here, so I did some digging with the help of AI (disclaimer). Of course, I welcome any corrections in order to properly credit the attendees, their contributions, or otherwise! And these are just from this one screenshot! Imagine all the other participants in a group of almost 100 inspiring leaders in their fields! We #HoldTheLine fighting alongside warriors like these! With cooperation and coordination such as this, I simply cannot wait to see what might be unveiled tomorrow for World Cancer Day! Advocacy / Coalition Leadership Laurel Comiter - Senior operations and strategy leader at the Cancer Vaccine Coalition (CVC). She helps coordinate high-level scientific, advocacy, and industry stakeholders to accelerate cancer vaccine development and awareness. Kristen Dahlgren - Founder & CEO of the Cancer Vaccine Coalition. Former NBC journalist turned cancer-vaccine advocate after her own diagnosis. Saranne Rothberg - Co-founder of the Cancer Vaccine Coalition and founder of the ComedyCures Foundation. Focuses on patient advocacy, fundraising, and public engagement around cancer innovation. Cheryl Stamm - Board President of the Cancer Vaccine Coalition. Governance, funding strategy, and long-term institutional backing for vaccine advocacy. Scientific & Academic Heavyweights (Core Vaccine / Immunology) Cornelis (Cees) Melief - One of the founding fathers of therapeutic cancer vaccines. Pioneered dendritic-cell and T-cell–based vaccine strategies. Legendary figure in tumor immunology. Catherine Wu - Dana-Farber oncologist and global leader in personalized neoantigen cancer vaccines (e.g., NeoVax). Her work underpins many mRNA and peptide vaccine strategies. Mary L. 'Nora' Disis - Director of the Cancer Vaccine Institute at UW. Pioneer in HER2/neu and tumor-antigen vaccines in breast and ovarian cancer. Central architect of the modern cancer-vaccine field. Glenn Dranoff - Harvard/Dana-Farber immunologist known for GM-CSF–based cancer vaccines. His work laid foundational principles still used in today’s platforms. Pawel Kalinski - Specialist in next-generation dendritic-cell vaccines and immune-polarization strategies to improve clinical responses. Hideho Okada - UCSF neurosurgeon-scientist developing brain tumor vaccines and T-cell therapies, especially for glioblastoma. Clinical Trial & Translational Oncology Leaders Paolo A. Ascierto - World-renowned melanoma immunotherapy clinician. While best known for checkpoint inhibitors, his work directly intersects with therapeutic cancer vaccines. Brian Czerniecki - Surgeon-scientist who has led dendritic-cell breast cancer vaccine trials, including preventive strategies. Marina Baretti - Johns Hopkins oncologist involved in clinical cancer vaccine trials, particularly rare GI and liver cancers. Tom Budd - Cleveland Clinic oncologist and principal investigator on breast cancer vaccine studies. H. Kim Lyerly - Duke surgeon-scientist and former Cancer Center director. Deeply involved in translating immunology into clinical cancer treatments, including vaccines. Industry, Biotech & Capital Enablers Linda Powers - CEO of Northwest Biotherapeutics, developer of DCVax dendritic-cell immunotherapy platforms. Represents real-world commercialization of personalized cancer vaccines. Katherine Andersen - Senior leader at HSBC Innovation Banking. Provides the capital infrastructure required to scale cancer-vaccine biotech companies. Scientific Institutions & Conveners Michael Powell - Senior American Association for Cancer Research (AACR) leader. Helps organize scientific working groups and cross-institution collaboration. Sean Malvey - AACR media/production lead. Responsible for disseminating and recording high-level scientific discourse — crucial for institutional visibility and education. Additional Participants Tony Ng - King’s College London cancer researcher with strong ties to translational oncology and drug development, often overlapping with immunotherapy ecosystems. Mitch Levine - Appears to be a senior oncology advisor/industry participant. Not a frontline vaccine scientist, but likely contributes regulatory, strategic, or institutional expertise. Samir (likely Samir Khleif) - Physician-scientist known for tumor immunology and cancer vaccine strategy, formerly involved in national-level cancer immunotherapy initiatives. Stephen (host/moderator – limited public info) Appears to be a meeting facilitator or allied contributor rather than a vaccine scientist.

$NWBO Great news here. This is proof of how legitimate #DCVax is becoming. All things are moving in our direction. Northwest Bio is the only named company in the article prnewswire.com/news-releases/…

I do wonder how much @elonmusk has heard of the cancer breakthrough miracle that is #NWBO and #DCVax ! He could do a world of good in support of it!

@hoffmann6383 If it's possible to just run out the clock, then how can they ever be forced(?) to comply? What's the penalty for noncompliance? I.e. running out the clock and submitting minimal/insubstantial documents?

@AXuring2 not really. if they can run out the clock and turn over minimal documents that is a win for the Ds

Spoofing Case Update - $NWBO v. Citadel, et al Case No.: 1:22-cv-10185 Docket: courtlistener.com/docket/6657959… Today we saw a letter filing by $NWBO asking for all the case management deadlines to be extended by 120 days. $NWBO's counsel blames the substitution of counsel, Les Goldman's passing, delay tactics by Defendants, among other things. I've attached an image of $NWBO's proposed deadlines. The Defendants do not consent to the extension of deadlines. Some interesting points in today's letter: ➡️Current Document Production "NWBio has so far produced 3,056 documents. Defendants have produced far less. Defendant G1 Execution Services LLC has only produced 10 documents, Defendant Virtu Americas LLC produced 26 documents, and Defendant Citadel Securities LLC produced 132 documents. The other Defendants—Canaccord Genuity LLC, GTS Securities LLC, Instinet LLC, and Lime Trading Corp.—have produced no documents at all." ➡️Nonparty Subpoenas "There have also been delays in receiving productions from nonparties. For example, in June 2025, NWBio served subpoenas to Depository Trust & Clearing Corporation (“DTCC”) and Financial Industry Regulatory Authority, Inc. (“FINRA”)—both of which are critical sources of relevant information concerning the trades at issue. Following NWBio’s persistent inquiries, DTCC only recently produced documents and FINRA is still gathering documents for future production, with partial production anticipated by mid-January and an uncertain timeline to complete production of archived data. Based on information gleaned from DTCC’s production, NWBio served additional follow-up requests to Defendants, for which responses are due today. Moreover, in October 2025, NWBio served a subpoena to nonparty OTC Link LLC, the scope of production for which is still being negotiated. All of the foregoing documents are critical to NWBio’s prosecution of this case."

ahem... $NWBO "It's gonna be very, very hard, in this day and age, to find companies where you can actually buy it for less than the actual value." youtube.com/shorts/SKb5vWF…

The Squeeze: If NWBO is one of the first companies to use this new regime tomorrow, it would signal an immediate transition from the manipulated OTC to the highly regulated LSE Main Market.

$NWBO Post 1/2 Thanks to @ATLnsider for this research which I will try to dig into. x.com/ATLnsider/stat… The Hidden "Cure" Trade in $NWBO Most investors are watching Northwest Biotherapeutics for one thing: the DCVax-L approval for brain cancer (GBM). While that is huge, it’s missing a much bigger picture that has quietly developed in the background. $NWBO has secured the rights to a next-generation technology that is currently curing "incurable" Stage 4 breast cancer in human trials. This isn't a mouse study. It’s happening right now in patients. In June 2024, NWBO announced an exclusive worldwide license with Roswell Park Comprehensive Cancer Center. This deal gave them control of the "Alpha-DC1" platform developed by Dr. Pawel Kalinski and Dr. Brian Czerniecki. Why does this matter? Because a recent patient case at Moffitt Cancer Center—using this exact method - just provided what looks like a "functional cure" for metastatic disease. If you are only valuing $NWBO on GBM, you are getting a free call option on a multi-billion dollar breast cancer franchise. Here is the breakdown of the "Dallas Carroll" signal and why it changes the investment thesis. The "Dallas Carroll" Signal - Proof of Concept To understand the value of the asset NWBO bought, look at the patient data coming out of Moffitt Cancer Center. Dallas Carroll was a young mother diagnosed with Stage 4 HER2-positive breast cancer. It had spread (metastasized) to her liver and bones. In standard oncology, this is a terminal diagnosis. You don't cure it; you just try to extend life by a few years with chemo. She enrolled in a trial led by Dr. Brian Czerniecki - Dr. Kalinski’s long-time partner and co-inventor of the tech NWBO licensed. The treatment was different. Instead of just injecting a vaccine into the skin, they injected these "Alpha-DC1" dendritic cells directly into her breast tumor. The result? The immune system woke up. It didn't just attack the breast tumor; it hunted down the cancer in her liver and bones and cleared them out. 18 months later, she is cancer-free (No Evidence of Disease). Surgeons were able to remove the primary mass and found the cancer was dead. This is called the "Abscopal Effect" - treating one spot to cure the whole body. This is the Holy Grail of cancer treatment, and NWBO now owns the rights to the platform that achieved it. How It Works Why did this work when other vaccines failed? Most solid tumors (like breast cancer) are "Cold." They build a wall around themselves that immune cells can't penetrate. You can have plenty of killer T-cells in your blood, but if they can't get inside the tumor, they are useless. The technology NWBO licensed (the Kalinski/Czerniecki IP) solves this two ways: 1. The GPS Signal (Chemokines): The "Alpha-DC1" cells are engineered to release massive amounts of chemical signals. Think of this like dropping a GPS pin inside the tumor that screams "HERE!" to the immune system. It physically pulls killer T-cells out of the blood and into the tumor. 2. The Training: Once the T-cells arrive, the vaccine trains them to recognize the specific "scent" of the cancer. Because they injected it directly into the tumor, the immune system learned to recognize the cancer at the source. Those trained cells then traveled through the blood to scrub the liver and bones clean. This effectively turns the patient's own tumor into its own vaccine factory.

Thanks to Lykiri on IHub, things seem to be progressing forward in the UK with $NWBO MAA for #DCVax-L as it was considered in the November CHM meeting:

This is big. From what I understand the Musella Foundation was threatened and forced to take this down. I don't know by who or what but now that they have posted the full webinar transcript signals that they no longer fear retribution. $NWBO

$NWBO Now you can download the FULL Transcript of Al Musella webinar December 5th. 2022 with UCLA doctor Linda Liau. AND FINALLY … with the missing Q&A section 💪🏻 bit.ly/49qCOVy Thanks @AlMusella 🙏🏻

@StonkMasterJ @tommba @TommyBaxendale can you share screenshots?

$NWBO Check out @TommBa message on Stocktwits stocktwits.com/TommBa/message… 🧐🧐🧐

$NWBO The system is being staged for a public release. These brief appearances are often referred to as "ghosting" or 'staging errors" in regulatory publishing systems, where data is pushed live before the official press release or front-end website is updated. --Gemini

$NWBO This is Linda Powers. If she didn’t needed help the last decade, she doesn’t need it now. Watch and learn.

For those who may not know... It's not just $NWBO... It's whole *market* manipulation. And the scum *will* pay 💰💰💰

Here is the most logical, evidence-based explanation for why market makers are keeping $NWBO share price extremely low and why this behavior is the opposite of normal market dynamics. ✅ The #1 Most Logical Reason: They Cannot Allow the Price to Rise Before Approval This is the core reasoning that explains EVERYTHING. If $NWBO has (imho): •2B+ synthetic / naked short shares •MHRA approval appears almost certain, with a 95% probability then any significant rise in the price before the approval would trigger: → Margin calls → Buy-ins → Collateral requirements jumping → A forced short squeeze BEFORE the news This would be catastrophic before they even get to the real danger: approval. They must keep the price flat or lower to survive until the announcement. ✅ Reason #2 They need liquidity to escape if the worst happens If approval arrives: MM’s and hedge funds with synthetic shorts will need: •massive volume •massive retail/institutional buying •massive price movement to cover or partially cover. BUT they cannot create that volume now. So the goal is: Keep the stock boring, flat, and unattractive. Avoid volume. Avoid buyers. Because if big money steps in early, it steals the liquidity needed for them to escape later. ✅ Reason #3 They are avoiding “price discovery” before the approval Remember this: $NWBO is not trading based on its company value. It trades based on short liabilities. If price discovery happened today, the stock would instantly price in: •UK approval probability •GBM market •Sawston’s MIA •Flaskworks •the lawsuit •institutional entry •partnership potential •global regulatory follow-on approvals Basic biotech math says NWBO’s pre-approval fair value is $2–$4. But if the price rises now real price discovery = margin calls = forced covering. So they prevent price discovery by: •spoof walls •dark pool volume •hit pieces •walking the bid •grinding charts to discourage buyers ✅ Reason #4 They are defending a “synthetic short pyramid” In a synthetic short structure, each additional synthetic share requires another layer of hedging. If the stock rises: •the hedges explode in cost, •the options offsets become invalid, •the synthetic chain collapses. This creates a pyramid structure that must stay stable until the binary event (approval).

$NWBO's Definitive Proxy Statement #tOTMA" target="_blank" rel="nofollow noopener">sec.gov/ix?doc=/Archiv… Annual Shareholder Meeting: Monday, December 29, 2025 at 2pm EST. Audio only link to be provided at a later time. Hope everyone (in the USA) had a good Thanksgiving. I'm finally getting around to reading $NWBO's proxy filed last Friday. Some quick/preliminary thoughts on the votes can be seen below. 1⃣To elect one member to our Board of Directors to serve as Class II Director for a term of three years; ​ I am tentatively voting "Withhold" on Pat Sarma's appointment. Mr. Sarma has no relevant business experience since about 2001, and even prior to said date the business experience doesn't appear relevant to $NWBO's field of business. From public court filings around 2010 it appears Mr. Sarma only dabbles in real estate. Mr. Sarma was part of $NWBO's compensation committee that contributed to the recent derivative lawsuit settlement. Mr. Sarma was on camera sleeping through the last ASM. We need accountability and relevant experience instead of a 'yes man' on the board. That's why I'm voting "Withhold" on Pat Sarma's appointment. 2⃣To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; I'm voting "For" the appointment of our accounting firm. ​ 3⃣To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase our authorized shares of common stock from 1,700,000,000 to 2,600,000,000, par value $0.001 per share (the “Common Stock”); I'm voting "For" the increase in authorized shares. We're a public company that doesn't have any revenue (minus a bit from Advent) so dilution is an unfortunate reality. ​ 4⃣To approve, on an advisory basis, the Company’s executive compensation; and I'm tentatively voting "Abstain" on the advisory vote for executive compensation. I want to see management bonuses and awards attached to timelines moving forward. That way, if timelines aren't met and dilution continues the management feels a bit of the same pinch retail does. From the derivative lawsuit, the awards appear setup in such a manner where the directors and executives don't feel the same pinch from dilution that the retail investor feels. Comparing ourselves to Novocure, the details surrounding how awards and bonuses are given at Novocure makes $NWBO's compensation sections look extremely barren of detail. ​ 5⃣To act upon such other matters as may properly come before the meeting or any adjournments or postponements thereof. Nothing to vote on with #5. Further Thoughts Above all else, I hope $NWBO starts to act like a public company. One that does quarterly conference calls. One that attempts to attract new investors with a slide deck. A company that attracts new investors through transparency into their plans, instead of having to parse 10 K/Qs for sparse details and then speculating on said sparse details. A company that attaches executive and director awards and bonuses to pre defined goals and timelines. If we are going to have to dilute, then at least behave in the way a customary public company would behave and try to attract new investors to offset some of the impact of further dilution. Even one of the consultants $NWBO hired referred to $NWBO as "more akin to a privately-held company". See Image 1. It's time we start acting in such a way to attract further investments and align awards and bonuses with transparent goals and timelines. $NWBO is on the verge of a regulatory approval for a groundbreaking cancer vaccine. It's amazing $NWBO has made it this far, but now it is time to buckle up and start acting in such a manner to attract further investments! This is my own preliminary thoughts as to the above linked Proxy. Everyone needs to do their own research and vote their own way. Respect differing opinions.

That would be about $500-$1,000+ per share, fully diluted ... possible in 5-10 years! Even $btc / #bitcoin can't offer those profit ratios — $NWBO would mean >200k % gains from current levels if/when they achieve stardom in #oncology #cancer treatment. That's 10k% gains/year

$NWBO Northwest Biotherapeutics is in discovery in its spoofing case against big market makers. A federal judge already gave Its market manipulation case the green light to go to trial. The company has a promising treatment for brain cancer. See the story of survivor @ThomasOwenMcCa1 below @ctv_jon @CTVNews Who would try to destroy a company working on a cure for glioblastoma? Greed is a powerful drug.